CCL20 and breast carcinoma: Through studies analyzing breast cancer patients’ serum, tumor tissue sample, survival prognosis, and pathologic response to taxane, we identified a chemokine, C-C motif chemokine ligand 20 (CCL20), that might predict the risk of taxane resistance in TNBC patients.